Based on proprietary tyrosine polymer technology, TYRX’s FDA-cleared lead product, AIGIS-Rx™, is an antibiotic-eluting mesh envelope into which pacemakers and defibrillators can be inserted prior to surgical implantation. Since coming onto the market in 2008, the product has been shown to substantially reduce the risk of high morbidity post-operative infections. TYRX has several antibiotic-eluting products that are in review or cleared for market including a fully resorbable CRM envelope, a surgical soft tissue repair mesh, and a hernia repair mesh.
TYRX won the 2012 Frost and Sullivan New Product Innovation Award, the Excellence in Surgical Products Award and the Web Health Award for HeartDeviceInfection.com. FierceMedicalDevices named TYRX as one of its “Fierce 15” Medical Device and Diagnostic Companies of 2012. The company was acquired by Medtronic, Inc. in early 2014.
Monmouth Junction, NJ
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.